Latest News
Dizal presents positive NSCLC data for DZD6008 and golidocitinib at ASCO 2026
1 June 2026 - Chinese biopharmaceutical company Dizal (SSE:688192) announced on Saturday the presentation of two studies in non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.One study evaluated...
TiumBio presents Phase 2a interim data for Tosposertib plus pembrolizumab at ASCO 2026
1 June 2026 - TiumBio Co Ltd (KOSDAQ:321550), a South Korea-based clinical-stage biopharmaceutical company, on Sunday announced clinical data for Tosposertib (TU2218), an oral dual inhibitor targeting transforming growth factor-beta (TGF-beta) and va...
ImmVira reports 100% CRR at 9 months in bladder carcinoma in situ with MVR-T3011
1 June 2026 - Chinese biopharmaceutical company ImmVira Group announced on Sunday that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented at the 2026 American Society of Clinical Oncology (ASC...
CARsgen presents long-term satri-cel follow-up results at 2026 ASCO Annual Meeting
1 June 2026 - CARsgen Therapeutics Holdings Limited (HK:2171), a Chinese developer of innovative CAR T-cell therapies, announced on Monday that the long-term analysis results of satricabtagene autoleucel (satri-cel, CT041) (an autologous CAR T-cell p...
Hanmi signs licensing deal with Lilly for sonefpeglutide
1 June 2026 - South Korea-based pharmaceutical company Hanmi Pharm. Co. Ltd. announced on Monday that it has entered into a licence agreement for the development, manufacturing and commercialisation of its biologic drug candidate sonefpeglutide (LAPS...